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Abstract: The current generation of novel anticancer therapies that are in preclinical and 
clinical development are based on exploiting our increasing understanding of the molecular 
and cellular basis of cancer development and progression. Accelerated rates of cell division 
and proliferation have been postulated to predispose to the development of malignant disease. 
The insulin-like growth factor (IGF) signaling system has an important physiological role in 
regulating cellular proliferation and apoptosis. This function has led to considerable interest in 
its relevance to neoplasia over the last decade. In this review, we give an overview of the IGF 
system physiology, discuss the epidemiological signiﬁ  cance of IGF signaling and neoplasia, and 
review the preclinical and clinical studies in targeting IGF receptors as cancer therapies.
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Insulin-like growth factor system physiology
Childhood growth in both humans and mice has been closely linked to the insulin-like 
growth factor (IGF) system (Liu et al 1993; Pollak et al 2004). It is largely constituted by 
two ligands (IGFI and IGFII) which interact with two receptors, IGF receptors I and II 
(IGFIR and IGFIIR). The complexity of the network has been signiﬁ  cantly underlined 
by the identiﬁ  cation of at least 6 IGF-binding proteins (IGFBPs), for which the 
functional characteristics have yet to be fully deﬁ  ned (LeRoith et al 2003). The 
presence of hybrid receptors between IGFIR and the insulin receptor (IR) has also 
been described (Federici et al 1997). Several proteins downstream of IGFIR have 
been identiﬁ  ed, including TOR, the insulin-receptor substrate (IRS) family, AKT, 
MAP kinase, and S6 kinase (Pollak et al 2004). The ultimate targets of these kinase 
cascades are members of the Ets and forkhead transcription factor families, the regu-
lation of which provide a mechanism by which the IGF system can elicit changes in 
gene expression that eventually mediate their effects on cellular proliferation and 
apoptosis (LeRoith et al 1995).
IGFI is largely produced in the liver and the upregulation of IGFI gene expression 
is stimulated by growth hormone (GH). It is also synthesized in extrahepatic sites 
(Jones et al 1995). It acts (along with IGFII) as a ligand for IGFIR, a cell-surface 
tyrosine kinase signaling molecule, which is highly related to the IR. It is a potent 
mitogen for a wide variety of cells and exerts its action by increasing DNA synthesis 
and by stimulating the expression of cyclin D1, which accelerates the cell cycle from 
G1 to S phase (Furlanetto et al 1994; Dufourny et al 1997). It also inhibits apoptosis 
by stimulating expression of Bcl proteins and suppressing expression of Bax (Minshall 
et al 1997; Parrizas et al 1997). On activation by its ligands, IGFIR phosphorylates the 
downstream targets mentioned above (Pollak et al 2004). Physiological activation of 
IGFIR and its hybrid receptors by overexpression alone is not seen, and thus, unlike 
with the epidermal growth factor (EGF) receptor family, activation of IGFIR requires Biologics: Targets & Therapy 2008:2(4) 856
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ligand-binding in most settings (Yee 2006). Consistent with 
this, apart from the endocrine response of IGFIR to plasma 
IGF1 levels, model systems have demonstrated autocrine 
production of ligands (Khandwala et al 2000). IGFIR also has 
very close homology to the IR, with their ATP-binding sites 
exhibiting 100% sequence identity, and their entire kinase 
domains sharing 84% sequence identity (Garcia-Echeverria 
et al 2004).
IGFII also has mitogenic and antiapoptotic actions 
which help regulate cell proliferation and differentiation. 
However it is believed to play a less important role in 
post-natal growth than IGFI, with animal experiments 
demonstrating that it exerts its inﬂ  uence during the early 
phases of growth and its role after birth is gradually replaced 
by IGFI (Yu and Rohan 2000). The IGFIIR appears to have 
no intracellular kinase domain and, unlike IGFIR, may not 
act as a signaling molecule, despite having a high afﬁ  nity 
for IGFII (MacDonald et al 1988).
IGFBPs are yet to be well deﬁ  ned but seem to have the 
potential to inﬂ  uence both stimulation and inhibition of IGFIR 
signaling, depending on the physiological context (Firth 
and Baxter 2002). The IGFBPs themselves are regulated by 
proteolysis regulated by various proteases (Baxter 2000). 
It has been observed that IGFBPs (particularly IGFBP3) 
have the same afﬁ  nity for IGFI as the IGFIR, leading to the 
suggestion that their inhibitory effect is mediated through 
binding to IGF1 and hence competitive inhibition of its 
effect on IGFIR. Alternatively, IGFBPs may promote IGFIR 
signaling by prolonging the IGF half-life through binding. 
Furthermore, the IGFBPs have also been found to have 
growth stimulatory actions independent of their binding to the 
IGF (Collett-Solberg and Cohen 1996; Kelley et al 1996).
In this review, we discuss the epidemiological studies 
that relate the IGF system to various types of malignant 
disease, and explore in more detail the in vitro, in vivo, and 
clinical studies with agents which target IGF receptors as 
cancer therapy.
IGF and cancer: epidemiology 
studies
There are a myriad of epidemiologic studies which have 
investigated the IGF system and its speciﬁ  c relationship 
with different cancer types. The results of such studies 
demonstrate that it is difﬁ  cult to identify individuals at risk 
of speciﬁ  c cancers by analysis of serum levels of the IGF 
system alone. Moreover, plasma levels of IGFI cannot be 
assumed to reﬂ  ect IGF signaling given the potential for both 
autocrine and paracrine activation of IGFIR. Most positive 
epidemiologic studies demonstrate a fairly modest increased 
risk of malignancy with high plasma IGFI levels. However 
chronic exposure to a modest risk factor may be more relevant 
to cancer development than infrequent exposure to a strong 
risk factor (Pollak et al 2004).
Prostate cancer is the malignancy that has been most 
studied in terms of an epidemiologic association with the 
IGF system. The results have been conﬂ  icting. However, 
the general consensus is that prospective case control studies 
have fairly consistently demonstrated a correlation between 
serum IGFI levels and prostate cancer risk. The strongest 
association applies to young men, with a four-fold increase 
in risk described for the highest compared to the lowest levels 
of IGFI in men under 59 years (Stattin et al 2004).
It has also been well documented that circulating IGFI 
levels are positively correlated with premenopausal (but not 
postmenopausal) breast cancer (Hankinson et al 1998). Other 
studies also have supported a positive correlation between 
breast cancer risk in general and IGFI levels (Peyrat et al 
1993; Vadgama et al 1999), although no difference exists 
between cases and case controls in some studies (Favoni 
et al 1995). Nevertheless there does seem to be a positive 
association between circulating IGFI levels and mammo-
graphic density (Maskarinec et al 2003), which in itself is 
strongly associated with breast cancer risk (Boyd et al 2002). 
In colon cancer, conﬂ  icting results exist with regards to a 
potential association, but most studies suggested that both 
IGFI and IGFII plasma levels were positively correlated with 
cancer risk compared to controls (El Atiq et al 1994; Ma et al 
1999; Palmqvist et al 2002).
Risk factor studies
Insulin and the IGF system constitute a common physiological 
basis for many well-deﬁ  ned malignancy risk factors described 
on an epidemiologic level, including raised body mass index 
(BMI), high calorie intake, higher birthweight, and lack of 
exercise.
The Million Women Study offers the most robust 
epidemiologic support for a strong association between 
BMI and cancer risk (Reeves et al 2007). A higher BMI 
was associated with a signiﬁ  cant increase in the risk of 
cancer for 10 out of 17 speciﬁ  c cancer types examined. 
Among postmenopausal women in the UK, 5% of all 
cancers were attributable to being overweight or obese. For 
endometrial cancer and adenocarcinoma of the oesophagus, 
BMI represented a major modiﬁ  able risk factor; about half 
of all cases in postmenopausal women are attributable to 
overweight or obesity. Obesity has also been implicated in Biologics: Targets & Therapy 2008:2(4) 857
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causing up to a 20% increase in breast cancer risk in those 
with a BMI over 30, with a 20% increase in risk of metastasis 
for women who have already been diagnosed with breast 
cancer (Freudenheim et al 1996).
Many studies have indicated that dietary control and 
reduced calorie intake may have a protective effect against 
cancer. Increased levels of IGFI have been associated with 
both high levels of energy intake and high dairy intake 
(Giovanucci et al 2003). Prostate cancer risk, in turn, has 
been associated with both increased IGFI levels and increased 
dairy intake, leading to speculation that we may in future be 
able to identify individuals at high risk who may beneﬁ  t from 
dietary restriction (Chan et al 2001; Pollak 2001). It has also 
been shown that intake of vegetables appears to decrease 
premenopausal breast cancer risk, with no isolated dietary 
factor explaining this effect (Freudenheim et al 1996). It is 
of interest that protection against carcinogenesis has been 
demonstrated by starvation and subsequently reversed by 
infusion of IGFI, suggesting a mediating role for IGFI 
in the protective effect of diet on carcinogenesis (Dunn 
et al 1997).
IGFI is very strongly associated with prenatal growth 
in particular. There are suggestions that high birthweight 
is positively associated with the risk of developing various 
cancer types including colorectal and prostate (Tibblin et al 
1995; Sandhu et al 2002). Two large prospective cohorts have 
also demonstrated that high birthweight is a risk factor for 
premenopausal breast cancer (Michels et al 2006). An indi-
vidual’s height has also been shown to contribute to a modest 
increase in cancer risk (Engeland et al 2003; Lawlor et al 
2003), although it has not been shown to have an association 
with plasma IGFI levels (Landin-Wilhelmsen et al 1994).
Regular physical activity whilst healthy can lead to 
up to a 20% reduction in risk of breast cancer later in life 
(Bernstein et al 2005). Furthermore, exercise after a breast 
cancer diagnosis has been strongly linked to improved 
quality of life and mortality risk reduction of up to 6% in 
those who perform the most physical activity (Holmes et al 
2005). There has however been no consistent demonstration 
that an association exists between IGFI levels and physical 
activity (Landin-Wilhelmsen et al 1994; Rudman and 
Mattson 1994).
IGF system pathophysiology
IGFI and IGFIR
IGFIR activation has been shown to induce proliferation and 
metastasis of cancer cells in vitro. This occurs either as an 
endocrine response to high levels of circulating IGFI or in 
response to autocrine production by tumor cells (Khandwala 
et al 2000). Pollak and colleagues (2004) speculated that, 
although there is evidence that experimental IGFI-positive 
cancers respond to ﬂ  uctuating levels of IGFI, some malig-
nancies probably respond to IGFI or IGFII produced in an 
autocrine or paracrine manner. This hypothesis would be 
consistent with the observation that IGF1R mRNA expression 
was decreased in prostate cancer tissue compared with normal 
prostate tissue, suggesting a role for chronic stimulation by 
an autocrine loop (Tennant et al 1996). Such a variation in 
IGFIR activation would imply that the efﬁ  cacy of any treat-
ment methods aimed to inhibit IGFIR signaling would not be 
reﬂ  ected by serum IGFI levels (Pollak et al 2004).
Several in vivo laboratory models of carcinogenesis have 
consolidated the purported relationship between the IGFI 
system and malignancy seen in epidemiologic research. Trans-
genic mice overexpressing human IGFI in basal epithelial 
prostate cells showed a 50% rate of prostate neoplasia by the 
age of 6 months (DiGiovanni et al 2000). In contrast, the inci-
dence of prostate cancer is markedly reduced in IGFI-deﬁ  cient 
mice (Majeed et al 2003). IGFI gene-deleted mice, which have 
25% of the circulating IGFI observed in normal mice, have 
also been used to study breast cancer development. Following 
carcinogen exposure, approximately 30% of IGFI-deﬁ  cient 
mice developed mammary tumors, compared to 60% of 
normal mice (Wu et al 2003). Transgenic mice that overex-
press growth hormone (GH) and consequently have higher 
circulating levels of IGFI, also develop mammary tumors at 
higher frequency (Tornell et at 1991). In contrast, hepatic 
carcinogenesis is attenuated in mice with diminished IGFIR 
signaling (Lu and Archer 2003).
In addition to involvement in carcinogenesis, it has 
also been proposed that IGFI has a signiﬁ  cant role in the 
development of metastases. Overexpression of the IGFIR in 
certain malignancies has been shown to be associated with 
aggressive behavior (Xie et al 1999). Evidence consistent 
with this includes the discovery that IGFI can upregulate 
VEGF gene expression and stimulate angiogenesis in a breast 
cancer cell line (Oh et al 2002). IGFI stimulation has also 
been shown to activate motility and migration of melanoma 
and neuroblastoma cancer cell lines (Meyer et al 2001; 
Satyamoorthy et al 2002).
IGFII and IGFIIR
IGFII is also implicated in malignancy. It has similar 
mitogenic and antiapoptotic mechanisms to IGFI, thereby 
also contributing to cell proliferation. Loss of genomic 
imprinting in the IGFII gene is often seen in malignancy Biologics: Targets & Therapy 2008:2(4) 858
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(Jarrard et al 1995; Oda et al 1997), and it is the gene most 
overexpressed in colorectal cancer cells (Zhang et al 1997). 
IGFII transgenic mice have a higher incidence of hepato-
cellular carcinoma and lymphoma, as well as several other 
tumors, compared to controls after 18 months of age (Rogler 
et al 1994). IGFII has also been observed to have higher 
levels of expression in cancer cells with a strong tendency 
to metastasize (Guerra et al 1996).
The IGFII receptor has no tyrosine kinase activity and 
therefore does not transduce any signals when binding to IGFII. 
It is therefore postulated to function as a tumor-suppressor 
(or ‘sink’), exerting its influence through its affinity for 
IGFII which would otherwise activate the IGFIR (Oates et al 
1998). Loss of IGFIIR has been demonstrated in cancer and 
is correlated with increased IGFIR activation (MacDonald 
et al 1998).
Targeting the IGF system: 
preclinical development
Three components of the IGF system have been identiﬁ  ed as 
potential targets for inhibiting its mitogenic and antiapoptotic 
properties: IGFIR regulators and ligands, the IGFIR itself, 
and downstream signaling pathways such as AKT and TOR 
(Figure 1).
IGFIR regulators and ligands
One potential upstream target in the IGF pathway is GH. 
Disrupting its action with the use of therapeutics such as 
somatostatin analogues (for example, octreotide) or GH 
releasing hormone antagonists has shown both anticancer 
efﬁ  cacy in preclinical models and a reduction in plasma 
IGFI levels (Pollak and Schally 1998; Letsch et al 2003). 
However, the results of clinical trials with these agents has 
been generally disappointing. This may be because GH has 
no effect on IGFII, which may be upregulated in response 
to diminished IGFI-induced IGFIR signaling. IGFII is not 
expressed in adult mice (DeChiara et al 1991), and it has 
therefore not yet been possible to model the approach of 
targeting the IGF system regulators and ligands in vivo 
accurately.
Agents generated to interfere directly with IGFI, IGFII, 
or the IGFBPs may represent an alternative mechanism for 
IGFII
IGFIIR
No signalling
Translation
TOR
AKT
PI3K
Peptide or small-molecule
inhibitors or antireceptor
antibodies
inhibitors
Kinase activity 
IGFIR expression
inhibitors
PTEN
IGFIR
IRSI
IGFI
Figure 1 Overview of initial IGFIR and IGFIIR receptor activation and downstream signalling. Main opportunities for possible pharmacological intervention targeted towards 
IGFIR are also indicated. Pharmacological intervention against downstream signalling pathways such as AKT and TOC have been extensively reviewed elsewhere. IGFIIR has 
no kinase domain and appears to act as a sink, preventing IGFII binding and activation of IGFIR.
Abbreviations: IGFIR, Insulin growth factor receptor I; IGFIIR, Insulin growth factor receptor II; IGFI, insulin growth factor I; IGFII, insulin growth factor II; IRSI, insulin receptor 
substrate I; TOR, phosphoinositide-3-Kinase; P13K, target-of-rapamycin.Biologics: Targets & Therapy 2008:2(4) 859
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inducing anticancer activity. One recent exciting example of 
this possible therapeutic intervention involves curcumin, an 
agent with anticarcinogenic and chemo-preventive properties 
found in high levels in turmeric. This agent has shown an 
ability to down-regulate the IGFI axis in MCF-7 cell lines 
(Xia et al 2007). The purported mechanism for this effect is 
increased sequestration of IGF ligands by IGFBP3, rendering 
IGFI unavailable for binding to and activation of IGFIR. 
Moreover, curcumin in combination with 5FU/oxaliplatin 
chemotherapy in vitro produced greater inhibition of growth 
and stimulation of apoptosis in colon cancer cells compared 
to 5FU/oxaliplatin alone (Patel et al 2008).
IGFIR
Monoclonal antibodies currently constitute the majority of 
agents that have been developed to target IGFIR, and were 
the ﬁ  rst agents that target IGF1R to enter clinical trials. 
Several antibodies directed against IGFIR have been devel-
oped and have shown a common anticancer mechanism of 
IGFIR down-regulation (Li et al 2000; Burtrum et al 2003; 
Maloney et al 2003). CP-751,871 is a fully human IgG2 
antibody with high afﬁ  nity for human IGF-1R, which has 
now entered human clinical trials (see below). It has been 
shown in preclinical studies to block binding of IGF1 to 
IGFIR, IGFI-induced receptor autophosphorylation, and 
induce the downregulation of IGFIR in vitro and in tumor 
xenografts. It has also demonstrated signiﬁ  cant antitumor 
activity both as a single agent and in combination with 
adriamycin, 5-ﬂ  uorouracil, or tamoxifen in multiple tumor 
models (Cohen et al 2005). Sachdev and colleagues (2003) 
examined in vitro and in vivo mechanisms of the monoclonal 
antibody, scFv-Fc, on MCF-7 breast cancer cells, and 
proposed that it potentially downregulates the IGFIR via the 
endosomal endocytic pathway. It was also noted that, aside 
from blocking IGFIR activation, scFv-Fc appeared to have 
direct antitumor properties, possibly by altering the distribu-
tion of cell cycle components. Another fully human antibody 
that targets IGFIR, IMC-A12, has shown antitumor effects 
in a number of cancers in vivo (breast, renal, pancreatic, 
multiple myeloma) by inducing IGFIR internalization and 
degradation, resulting in a signiﬁ  cant reduction in cell surface 
receptor density (Rowinsky et al 2007; Wu et al 2007).
Small molecule tyrosine kinase inhibitors of IGFIR have 
also been developed and recently entered human clinical 
trials. Potent antitumor effects of small molecule inhibitors 
have been demonstrated in preclinical studies for a variety 
of cancer types. Activity of the tyrosine kinase inhibitor, 
NVP-ADW742, has been demonstrated against multi-drug 
resistant multiple myeloma cell lines (Mitsiades et al 2004). 
In vivo, the orally bioavailable compound, NVP-AEW541, 
inhibited IGFIR signaling in tumor xenografts and signiﬁ  -
cantly reduced the growth of IGFIR-driven ﬁ  brosarcomas 
(Garcia-Echeverria et al 2004). Another recent study utilized 
an alternative IGFIR kinase inhibitor, PQIP, for once daily 
oral administration, and showed robust antitumor efﬁ  cacy 
in colorectal cancer xenografts which was correlated with 
the degree and duration of inhibition of tumor IGFIR 
phosphorylation by the compound (Ji et al 2007). Moreover, 
a novel class of IGFIR/IR receptor inhibitors have also 
shown potential clinical application with their antipro-
liferative and proapoptotic activity leading to signiﬁ  cant 
inhibition of the growth in vivo (Haluska et al 2006). One 
potential concern regarding inhibition of IGF1R tyrosine 
kinase is the close homology of IGFIR to the IR, and the 
possibility of drug-induced hyperglycemia. However, early 
results in clinical trials have so far been favorable with 
regard to potential detrimental effects on glucose metabolism 
(see below).
The use of dominant-negative IGFIR is an alternative 
therapeutic strategy which is at an earlier stage of preclinical 
development, but has also shown promise. The develop-
ment of metastases from breast cancer cells has been shown 
to be inhibited by a truncated dominant-negative IGFIR. 
By transfecting a dominant-negative form of IGFIR into 
metastatic breast cancer cell lines, Dunn and colleagues 
(1998) showed that metastases were signiﬁ  cantly decreased, 
although this method did not signiﬁ  cantly suppress primary 
tumor growth. These ﬁ  ndings were supported by an in vivo 
study of colon cancer which showed decreased tumor growth, 
cell proliferation, and vascular endothelial growth factor 
(VEGF) expression in nude mice who were transfected 
with an alternative truncated dominant-negative form of 
IGFIR (Reinmuth et al 2002). Moreover, tumor formation 
and metastatic abilities were reduced and survival increased 
with the use of this method in vivo in Ewing’s sarcoma cells 
(Scotlandi et al 2002).
Antisense RNA and gene disruption also constitute 
preclinical strategies with early success. Reduction in IGFIR 
expression, cancer cell growth, and proliferation have been 
shown in vivo with the use of this method (Sell et al 1994; 
Bohula et al 2003). Chernicky and colleagues (2000) also 
demonstrated in vivo efﬁ  cacy of this method in mammary 
tumors: injection of IGFIR antisense RNA into nude mice led 
to both a delay in tumor formation and a dramatic reduction in 
tumor size. As with the studies examining dominant-negative 
IGFIR, the studies looking at antisense RNA as a therapeutic Biologics: Targets & Therapy 2008:2(4) 860
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strategy have suggested that IGFIR particularly plays a role 
in progression and metastasis of cancer.
Downstream targets
Downstream proteins in the IGF system such as AKT, TOR, 
or MAP kinase represent alternative targets for inhibition of 
IGFIR signaling, and may not be associated with compensatory 
mechanisms for decreased IGFIR signaling which could exist 
further upstream. The rationale for such ‘cross-talk’ further 
upstream is validated by the observations that resistance to 
HER2 inhibition is associated with increased IGFIR signaling 
(Nahta et al 2005), and also that suppression of IGFIR signaling 
led to inhibition of non-small cell lung cancer proliferation 
by geﬁ  tinib (Morgillo et al 2007). A number of agents which 
target these downstream proteins are in preclinical and clinical 
development and have been extensively reviewed elsewhere.
Targeting the IGF system: clinical 
development
All the clinical trials that have been published to date have 
involved strategies aimed at blocking the IGFIR. Targeting 
IGFIR represents a conceptually different therapeutic 
approach compared to the rationale employed for the use of 
some other biological treatments, such as imatinib, which acts 
on single molecular targets that are unique or overexpressed 
in tumor cells compared to normal cells. Although the IGF 
system is expressed in a wide range of malignancies, it is also 
expressed ubiquitously in normal human tissue. Thus it is 
likely that agents which target IGFIR will have a therapeutic 
window with the optimal dose being that which inhibits 
IGFIR function that sustains tumor cell growth without 
compromising survival of normal cells. Currently there is 
relatively little clinical data arising from the large body of 
preclinical research in this area. Published literature (mostly 
abstracts) on clinical trials of IGFIR inhibitors have begun 
to emerge during recent years, and it is likely that mature 
clinical data will continue to emerge for these studies in the 
near future. Almost all of the published clinical information 
arises from early phase clinical trials. These trials utilize 
IGF1R inhibitors either as monotherapy or as part of combi-
nation therapy regimens. Clinical studies with somatostatin 
analogues, AkT, TOR, and MAP kinase inhibitors have been 
extensively reviewed elsewhere. In this section, we focus on 
the emerging clinical studies with IGFIR inhibitors.
IGFIR inhibitors: Single agent studies
Three phase I studies of monoclonal antibodies targeted 
against IGF1R have been published (Lacy et al 2006; 
Haluska et al 2007; Higano et al 2007). CP-751,871 is a 
fully human IgG2 monoclonal antibody (mAb) antagonist 
of IGF-1R used in two of the studies (Lacy et al 2006; 
Haluska et al 2007). The other trial studied IMC-A12, a 
fully human IgG1 mAb also directed against IGF-1R (Higano 
et al 2007).
Toxicity analyses
Safety and tolerability has to date been favorable with the 
use of these agents in phase I studies. One of the phase I 
studies of CP-751,871 did not deﬁ  ne the maximum tolerated 
dose (MTD) of CP-751,871 as it exceeded the maximum 
feasible dose (MFD) of 20 mg/kg (Haluska et al 2007). There 
were no treatment-related toxicities greater than NCI-CTC 
grade 3 observed in this study. One grade 3 episode of fatigue 
and arthralgia occurred at the maximal dose administered. 
Grades I/II toxicities included hyperglycemia, anorexia, 
elevated AST/GGT, diarrhoea, hyperuricemia, and fatigue. 
Two patients received at least 16 three-weekly cycles without 
demonstrating evidence of cumulative toxicity, and patients 
were able to tolerate repeated cycles of CP-751,871 at doses 
several orders of magnitude above the minimal biologically 
effective concentration (Cohen et al 2005).
These toxicity findings were consistent with the 
observation from two other monotherapy studies of 
IGFIR antibodies (Lacy et al 2006; Higano et al 2007). 
No dose-limiting toxicities (DLTs) were reported in the 
phase I study of CP-751,871 in patients with advanced 
multiple myeloma (MM). One DLT (grade 3 hyperglycemia) 
was observed in the phase I study of IMC-A12, but 
otherwise toxicities were again limited to grade 1 (pruritis, 
rash, discolored feces) and grade 2 (anemia, psoriasis, 
hyperglycemia, infusion-related reaction) levels despite 
a more intensive weekly dosing regimen with this IGFIR 
inhibitor.
Prior to clinical evaluation, hyperglycemia was 
considered to be the likely drug-related toxicity in clinical 
trials, and certainly it is the most common laboratory 
related abnormality from current evidence (albeit nearly 
all at grade 1 or 2 level). However, at a preclinical level, 
it was anticipated that monoclonal antibodies were 
speciﬁ  c enough to avoid inhibition of the IR despite its 
extensive homology with IGFIR. Furthermore, Haluska 
and colleagues (2007) established that the Cmax with 
repeated dosing of CP-751,871 in their trial was less than 
a third of what earlier investigation had shown to be the 
concentration necessary for binding to the IR (Cohen et al 
2005; Haluska et al 2007).Biologics: Targets & Therapy 2008:2(4) 861
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The above data has therefore led to an alternative 
hypothesis which does not attribute raised glucose levels to 
IR-binding by IGFIR inhibitors. Alternatively it has been 
suggested that IGFI has an important role in regulation 
of glucose homeostasis, whereby inhibition of its ligand 
action on IGFIR could lead to hyperglycemia. Data 
consistent with this theory includes the ﬁ  nding that IGFI 
administered to humans results in hypoglycemia (Guler 
et al 1987; Schmitz et al 1991), as well as the knowledge 
that recombinant IGFI has been shown to improve glucose 
control in type II diabetics by increasing insulin sensitivity 
(Moses et al 1996). This potential shift in conception of the 
causality of hyperglycemia could have signiﬁ  cant implica-
tions in the long-term for use of monoclonal antibodies over 
small molecule tyrosine kinase inhibitors in the targeting of 
IGFIR, as the main purported advantage of immunological 
treatments is that they are more speciﬁ  c to the IGFIR. 
Small molecule inhibitors already have the advantage of 
being available as a convenient oral therapy. Furthermore, 
there is a body of preclinical evidence that suggests IR 
(as well as IGFIR) potentially has a role in carcinogenesis 
itself, thereby suggesting that CP-751,871 does not reach 
appropriate pharmacologic concentrations to achieve an 
optimal anticancer effect on human insulin receptors.
An interesting observation in the endocrine analysis of 
three-weekly administration of CP-751,871 is that insulin 
levels cumulatively increased in patients who received 
prolonged administration. This was therefore proposed as 
a potential compensatory mechanism for control of hyper-
glycemia caused by IGFI inactivation (Haluska et al 2007). 
Further endocrine studies are required in future clinical trials 
for further characterisation of all of the above ﬁ  ndings.
Clinical responses
Although a secondary endpoint for phase I studies, 
encouraging clinical responses have been observed in 
preliminary data from studies of IGFIR inhibitors as single 
agents. Weekly administration of IMC-A12 induced stable 
disease in 2 of 11 patients for over 9 months at the time of 
reporting, with another three patients showing disease stability 
after their ﬁ  rst 4-weekly cycle with dose escalation continuing 
(Higano et al 2007). Furthermore, there was 1 near complete 
response (CR) and 2 partial responses (PRs) seen in patients 
with MM treated with CP-751,871 in combination with 
dexamethasone (Lacy et al 2006). Haluska and colleagues 
(2007) reported that 7 of 12 patients with advanced solid 
tumors receiving CP-751,871 at 20 mg/kg had small reduc-
tions in measurable tumor size. Furthermore, two patients 
had prolonged disease stabilization for over 48 weeks. These 
ﬁ  ndings are encouraging given the advanced refractory disease 
of patients who enter into early phase clinical trials.
IGFIR inhibitors: combination therapy 
studies
Synergy between biological treatments and chemotherapies is 
not necessarily easily predicted. Successes such as trastuzumab 
in combination with taxanes (Slamon et al 2001) are outweighed 
by other failed combination attempts (Herbst et al 2004). It has 
been suggested that IGFIR inhibitors may act in either way 
and this could be dependent on the strategy used: monoclonal 
antibody treatments are thought to potentially synergize with 
chemotherapy by lowering the apoptotic threshold of cancer 
cells, while it is speculated that tyrosine kinase inhibitors may 
interfere with the cell cycle speciﬁ  c effects of chemotherapy by 
blocking progression through to S-phase (Yee 2006).
Two trials involving IGFIR inhibitors in combination with 
chemotherapy have been reported. One phase I trial analyzed 
the combination of varying doses of CP-751,871 administered 
with docetaxel (75 mg/m2) at 3-weekly intervals in patients 
with advanced cancer (Attard et al 2006). Again the MTD 
had not been reached in this trial and toxicities experienced 
in patients were felt to be attributable to the chemotherapy. 
Only a transient grade 1 episode of hyperglycemia was noted, 
and this had occurred following steroid use prior to taxane 
administration. No cardiac toxicity was observed on serial 
echocardiograms. Response rates were again encouraging 
with 5 patients receiving CP-751,871 alone reported as having 
stable disease.
Phase II evidence has now begun to emerge with an 
interim analysis of paclitaxel and carboplatin with or without 
CP-751,871 in stage IIIb/IV NSCLC recently being reported 
(Karp et al 2007). Impressive response rates were observed 
in the 73 patients analysed, although more data with regard 
to toxicity emerged. The response rate was 46% in the IGFIR 
inhibitor group compared with 32% in the chemotherapy alone 
group, and it was noted in particular that 52% of the nonad-
enocarcinoma patients responded to treatment. Furthermore, 
a PR was observed in a patient who received single agent 
CP-751,871 following progression on chemotherapy alone. 
Hyperglycemia (20% vs 10%), fatigue (15% vs 8%), and 
neuropathy (10% vs 4%) were, however, found to be more 
prevalent in the IGFIR inhibitor group.
Biological markers
It is clear from this review that the IGF system has a role 
implicated in several cancer types including breast, prostate, Biologics: Targets & Therapy 2008:2(4) 862
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multiple myeloma, and sarcoma. However it is likely that 
different subtypes of patients with each of these cancers 
(for example, premenopausal breast cancer) may respond 
to IGFIR blockade more than other subtypes. It is therefore 
of great importance to discover molecular markers that 
can predict a high probability of clinical beneﬁ  t from such 
treatment. Studies performed of cells which are IGFIR 
activated and yet lack a phenotypic response would suggest 
that this may not be straightforward (Yee 2006). Furthermore, 
as already discussed, IGF-related tumors are not necessarily 
associated with overexpression of IGFIR (as is the case 
with HER2), and plasma levels of IGFI and IGFII do not 
reﬂ  ect IGFIR activation given that autocrine and paracrine 
mechanisms are likely to be involved also.
The most interesting biomarker study reported so far 
details the detection of circulating tumor cells (CTCs) with 
CP-751,871 blockade of IGFIR (de Bono et al 2007). IGFIR 
expression is detectable by immunoﬂ  uorescence on CTCs. 
CTCs were commonest in advanced hormone-refractory 
prostate cancer patients, with detectable IGFIR expression 
on the CTCs showing an association with higher frequency of 
PSA declines by over 50%. However, it was not possible to 
establish a dose-effect relationship with only 33% of patients 
having detectable CTCs at initiation of treatment. This lack of 
sensitivity represents the main limitation of this technique as 
a biomarker, and therefore its current use appears to be most 
promising in patients with large tumor burdens.
Future developments
Several phase II trials involving IGFIR inhibitors are now 
underway, the results of which are eagerly anticipated. Prostate 
cancer has been an area of particular interest. However, 
continuing research is also focused on trying to identify cancers 
at a biological level which might be susceptible to IGFIR anti-
body therapy, with the further characterization and early clinical 
trial use of appropriate biomarkers of particular importance.
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